Brief: Sprint Bioscience Q2 Operating Loss Widens To SEK 14.7 Million
Aug 13 (Reuters) - Sprint Bioscience AB SPRINT.ST :
* Q2 NET SALES SEK 0 MILLION VERSUS SEK 5.8 MILLION YEAR AGO
* Q2 OPERATING RESULT SEK -14,7 (-10,1) MILLION
Source text for Eikon: ID:nWkrntXgT
Further company coverage: SPRINT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Sprint Bioscience AB
See all newsBrief: Sprint Bioscience Q1 Operating Loss SEK 14.3 Mln
Brief: Sprint Bioscience Completes Strategic Evaluation Of STK25 Program
Brief: Sprint Bioscience Appoints Jenni Björnulfson As CFO
Brief: Sprint Bioscience Reports Positive Proof-Of-Concept Results From Program In CKD
Brief: Sprint Bioscience Reports Positive Results From The Vrk1 Program